EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High SARS‐CoV‐2 Exposure in Rural Southern Mozambique After Four Waves of COVID‐19: Community‐Based Seroepidemiological Surveys

Áuria de Jesus, Rita Ernesto, Arsénia J Massinga iD, Felizarda Nhacolo, Khátia Munguambe, Alcido Timana, Arsénio Nhacolo, Augusto Messa iD, Sérgio Massora, Valdemiro Escola, Sónia Enosse, Rufino Gunjamo und 7 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Áuria de Jesus und 18 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Rural Population. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, European and Developing Countries Clinical Trials Partnership, German Federal Ministry of Health (BMG) COVID-19 Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mozambique was one of many African countries with limited testing capacity for SARS‐CoV‐2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age‐specific seroprevalence of SARS‐CoV‐2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination.

Methods

We conducted four community‐based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS‐CoV‐2 antibodies. An age‐stratified (0–19, 20–39, 40–59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS‐CoV‐2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT‐qPCR.

Results

SARS‐CoV‐2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals < 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys.

Conclusions

A high seroprevalence to SARS‐CoV‐2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, ViralRural PopulationHumansMozambiqueSeroepidemiologic StudiesAdultAdolescentChild, PreschoolMiddle AgedYoung AdultChildFemaleMaleInfantInfant, NewbornAgedImmunoglobulin GImmunoglobulin M

Stichwörter der Autor:innen

COVID‐19MozambiqueSARS‐CoV‐2antibodiesseroprevalenceserosurveysub‐Saharan Africa

Substanzen

Antibodies, ViralImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
  • Faculdade de Medicina, Universidade Eduardo Mondlane (UEM), Maputo, Mozambique.
  • Instituto Nacional de Saúde (INS), Ministério da Saúde, Marracuene-Maputo, Mozambique.
  • Mozambique Country Office, World Health Organization, Maputo, Mozambique.
  • Regional Office for Africa (AFRO), World Health Organization, Brazzaville, Republic of Congo.
  • ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

ORCID-Profile: Arsénia J Massinga, Augusto Messa, Inácio Mandomando

Förderung

  • Bill and Melinda Gates Foundation
  • European and Developing Countries Clinical Trials Partnership
  • German Federal Ministry of Health (BMG) COVID-19 Research and Development Fund
  • COVID-19 Solidarity Response Fund
  • World Health Organization

Zitieren

APA

de Jesus, Á., Ernesto, R., Massinga, A. J., Nhacolo, F., Munguambe, K., Timana, A., Nhacolo, A., Messa, A., Massora, S., Escola, V., Enosse, S., Gunjamo, R., Funzamo, C., Mwenda, J. M., Okeibunor, J., Garcia-Basteiro, A., Guinovart, C., Mayor, A., & Mandomando, I. (2024). High SARS‐CoV‐2 Exposure in Rural Southern Mozambique After Four Waves of COVID‐19: Community‐Based Seroepidemiological Surveys. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13332

Vancouver

de Jesus Á, Ernesto R, Massinga AJ, Nhacolo F, Munguambe K, Timana A, et al. High SARS‐CoV‐2 Exposure in Rural Southern Mozambique After Four Waves of COVID‐19: Community‐Based Seroepidemiological Surveys. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13332

BibTeX
@article{deJesus2024,
  author = {de Jesus, Áuria and Ernesto, Rita and Massinga, Arsénia J and Nhacolo, Felizarda and Munguambe, Khátia and Timana, Alcido and Nhacolo, Arsénio and Messa, Augusto and Massora, Sérgio and Escola, Valdemiro and Enosse, Sónia and Gunjamo, Rufino and Funzamo, Carlos and Mwenda, Jason M and Okeibunor, Joseph and Garcia-Basteiro, Alberto and Guinovart, Caterina and Mayor, Alfredo and Mandomando, Inácio},
  title = {High SARS‐CoV‐2 Exposure in Rural Southern Mozambique After Four Waves of COVID‐19: Community‐Based Seroepidemiological Surveys},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13332}
}
Kostenlos starten →